"Protocol 17S-MC-HBEH Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD) (The PRESENCE Study)"
The purpose of this study is to determine how LY3154207 compares with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson?s disease dementia.
The primary objective is to test the hypothesis that LY3154207 administered at 10 mg, 30 mg, and/or 75 mg daily (or 50 mg based on interim analysis) (QD) oral dosing for 12 weeks will result in significant improvement in cognition in subjects with mild-to-moderate Parkinson's Disease Dementia (PDD) compared with placebo.
Participants will be paid for their participation.
- IRB Number: 1709267154
- Research Study Identifier: TX8499
- Principal Investigator: Jared Brosch, MD